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Abstract
Tissue engineering aims to generate or facilitate regrowth or healing of damaged tissues by applying a
combination of biomaterials, cells, and bioactive signaling molecules. In this regard, growth factors
clearly play important roles in regulating cellular fate. However, uncontrolled release of growth factors has
been demonstrated to produce severe side effects on the surrounding tissues. In this study,
poly(lactic-co-glycolic acid) (PLGA) microspheres (MS) incorporated three-dimensional (3D) CORAGRAF
scaffolds were engineered to achieve controlled release of platelet-derived growth factor-BB (PDGF-BB)
for the differentiation of stem cells within the 3D polymer network. Fourier transform infrared
spectroscopy, energy-dispersive X-ray spectroscopy, scanning electron microscopy, and microtomography
were applied to characterize the fabricated scaffolds. In vitro study revealed that the CORAGRAF-PLGAPDGF-BB scaffold system enhanced the release of PDGF-BB for the regulation of cell behavior. Stromal
cell attachment, viability, release of osteogenic differentiation markers such as osteocalcin, and
upregulation of osteogenic gene expression exhibited positive response. Overall, the developed scaffold
system was noted to support rapid cell expansion and differentiation of stromal cells into osteogenic
cells in vitro for bone tissue engineering applications.
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Abstract
Tissue engineering aims to generate or facilitate regrowth or healing of damaged tissues by
applying a combination of biomaterials, cells, and bioactive signaling molecules. In this regard,
growth factors clearly play important roles in regulating cellular fate. However, uncontrolled
release of growth factors has been demonstrated to produce severe side effects on the
surrounding tissues. In this study, poly (lactic-co-glycolic acid) (PLGA) microspheres (MS)
incorporated three-dimensional (3D) CORAGRAF scaffolds were engineered to achieve
controlled release of platelet-derived growth factor-BB (PDGF-BB) for the differentiation of
stem cells within the 3D polymer network. Fourier transform infrared spectroscopy, energydispersive X-ray spectroscopy, scanning electron microscopy, and microtomography were
applied to characterize the fabricated scaffolds. In vitro study revealed that the CORAGRAF–
PLGA–PDGF-BB scaffold system enhanced the release of PDGF-BB for the regulation of cell
behavior. Stromal cell attachment, viability, release of osteogenic differentiation markers such
as osteocalcin, and upregulation of osteogenic gene expression exhibited positive response.
Overall, the developed scaffold system was noted to support rapid cell expansion and
differentiation of stromal cells into osteogenic cells in vitro for bone tissue engineering
applications.

Keywords: CORAGRAF; PLGA; Microsphere; Stromal cell; Platelet-derived growth factor;
Osteogenic
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Introduction
Calcium phosphate (CaP) scaffolds composed of beta-tricalcium phosphate,1
hydroxyapatite, chitosan,2 and their composites3 are ideal for bone repair owing to their
biocompatibility, adjustable degradation rates, and excellent bioactivity.4-6 However, they are
not osteoinductive in nature, and materials such as chitosan are brittle and exhibit poor cell
attachment. 7-9 Although scaffolding materials are critical for tissue regeneration, researchers
have found that growth factor stimulation, both in vitro and in vivo, is also vital. Reports have
shown that the overall functional bioactivity of scaffolds, including bone or cartilage healing,
improved following incorporation of growth factors, such as transforming growth factor-beta
(TGF-b), vascular endothelial growth factor (VEGF), and bone morphogenetic proteins
(BMPs), into the biomaterial scaffolds.10 Among the various well-known growth factors,
platelet-derived growth factor-BB (PDGF-BB) is a potent mitogen that can induce
angiogenesis and direct cell migration, and is involved in vessel maturation and stabilization.11
In recent times, although increasing numbers of drug-loaded scaffolds have been designed
using different structures and materials, the undesirable drug burst release phenomenon
associated with rapid drug diffusion from these scaffolds has reduced the effectiveness of the
drugs, thus constraining the application of these biocomposites.12-13 Nevertheless, studies have
shown that incorporation of drug-loaded microspheres (MS) into composite scaffolds with
gradient structure could effectively solve the problem of drug burst release phenomenon.14-16
It has been reported that, in addition to scaffolds and growth factors, human primary cells (e.g.
mesenchymal stem cells (MSC), osteocytes, and endothelial cells) supplemented with growth
factors or cytokines can also be used to repair bone tissues.17 Growth factors such as BMP2,
TGF-b, and Wnt ligands affect cellular migration and proliferation as well as osteogenic
differentiation of MSC during bone repair.18-19 In addition, they can regulate the expression of
Runt-related transcription factor 2 (Runx2) and osterix (Osx) through intracellular proteins or
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transcription factors, including b-catenin, Smad1/5, and Smad2/3.20 Ideally, the key growth
factors can be programmatically encapsulated and embedded into CaP scaffolds, and then
released into the microenvironment of the bone graft after being implanted. These growth
factors can subsequently stimulate the expression of genes responsible for osteoblastic
differentiation from MSC to pre-osteoblasts and active osteoblasts21 through a variety of
signaling pathways.22
Coral has been used as a bone substitute for more than a decade. This material makes a
good choice for fabricating scaffolds because it can be easily molded into any desired shape
and size.23 Earlier reports have shown that coral-based biomaterials are biocompatible and
osteoconductive.24-25 Besides, coral can be used as a delivery system for the bone growth
factors owing to its adhesive property.26 The coral graft has interconnected porous structures
that offer a large surface area for cell attachment. In addition, it also provides a suitable
environment for nutrient transfer and physiological support. Coral-based biomaterials, such as
Biocoral and Algipore®, have been widely used in the augmentation of periodontal defects and
nonunion in pre-clinical and clinical models.27-28 Poly(lactic-co-glycolic acid) (PLGA) has
been extensively employed in the form of microspheres or nanospheres for the controlled
delivery of peptides or proteins owing to its excellent biological properties, including
biodegradability, biocompatibility, nontoxicity, bacteriostaticity, and strong adhesion.29
During such encapsulation process the biological activity of the growth factors were much
retained as the unwanted degradation of growth factors was prevented. Although, adsorption
of growth factors onto the surface of natural of synthetic polymer matrices will allow the local
delivery of growth factors this process will lead in compromising the release kinetics.30-31 For
a successful tissue engineering application it’s advantageous to develop a construct that
contains a carrier for successful delivery of growth factors and a 3D scaffold of cell attachment
and differentiation.
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Although previous studies have reported on the incorporation of MS into
nanofibrous scaffold for the controlled release of growth factors such as PDGF-BB,32-33 these
scaffolds have limited hard-tissue engineering applications owing to their biomechanical
properties. Consequently, in the present study, for the first time, we attempted to develop an
ideal hard scaffold system based on the hypothesis that culturing of bone marrow stromal cells
in coral graft with controlled release of PLGA–PDGF-BB could induce differentiation of bone
marrow stromal cells to bone-like cells. Such simple yet effective approach could pave the way
for further developments in the field of implantable scaffolds for bone tissue engineering.

Materials and Methods
Materials
PLGA (glycolic acid:lactic acid at a ratio of 50:50, Mw=64 kDa) was purchased from
DURECT Corporation (Pelham, AL, USA). Recombinant PDGF-BB was obtained from Life
Technologies (Invitrogen, USA). Dichloromethane, tetrahydrofuran, hexane, and polyvinyl
acid (PVA) were purchased from Sigma Aldrich (USA). All the other chemicals used were of
analytical grade.

Preparation of Coragraft scaffold

Coral from the Porites species was processed using lab standardized protocol. Debris was
washed out of the coral using distilled water. Coral was cut and processed into blocks of 5.0
mm X 5.0 mm according to the requirements of the study. These cubical were treated
chemically followed by freeze drying. Samples were then radiosterilized at Malaysian Nuclear
Agency using gamma irradiation.

Preparation of PDGF-loaded MS by double emulsion method
5

The MS were prepared by using the double emulsion method.34 The PVA solution was prepared
by adding 5 g of PVA to 100 ml of distilled water, and the mixture was heated and mixed using
a thermal magnetic stirrer until all the PVA dissolved. Subsequently, the PLGA emulsion was
dropped into the PVA solution using a syringe, and the solution was sonicated for 20 s. Then,
the solution was left on a magnetic stirrer for 4 h. The MS were collected by centrifugation in
a 50-ml centrifuge tube. The collected solid MS were washed with distilled water at least thrice,
freeze-dried, and stored at −80°C.
The main water-in-oil (abbreviated as w/o) emulsion was prepared by emulsifying PDGF-BB
(PDGF- BB 25 µg/ml in a buffer of sodium acetate at pH=6.3, specific volume (1 ml) of 10%
PLGA (in dichloromethane solution via exploiting a sonicator at 15W (Dakshin, India) for 20s
over an ice bath. The prepared w/o emulsion was subsequently mixed with 2 ml of PVA
solution (1% in water) by agitation to establish a secondary water-in-oil-in-water (abbreviated
as w/o/w) emulsion. Subsequently, the solution was stirred in a magnetic stirrer for 3h at room
temperature to evaporate dichloromethane and the resulting solution was centrifuged (2500g,
5 minutes) to yield microspheres. The yielded microspheres carefully rinsed with deionized
water multiple times, lyophilized and subsequently stored in vacuumed cabinet.

Incorporation of PLGA MS into three-dimensional CORAGRAF
The PLGA MS with FITC-BSA were incorporated into three-dimensional (3D) CORAGRAF
scaffolds , The PLGA MS with FITC-BSA were prepared by using the double emulsion method
where 1g of PLGA was dissolved in 10 ml of dichloromethane and emulsified with 100μl of
FITC-BSA solution employing a sonicator at 200 V for 20 s, microspheres were then collected
through freeze-dry method. Briefly, 5 mg of dry PLGA MS were suspended in 500 μl of
hexane. Subsequently, 80 µl of the suspension was cultured into the block scaffold, and the
scaffold was forsaken in room atmosphere for half an hour to allow the evaporation of the
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solvent. Then, another 80 μl of the suspension were seeded on the opposite side of the coragraf
scaffold. The entire step has been repeated frequently for two times, leading to the
incorporation of approximately 5 mg of MS onto the scaffold. After that, the scaffold was
treated with a mixed solvent comprising hexane/THF (90/10 v/v) to anchor the MS on the
scaffold and lyophilized to get rid of the solvent. As a control, scaffolds with PLGA MS
deprived of growth factors were employed. The concentration of the MS precursor and seeding
times were adjusted accordingly to control the accumulated amount of MS on the scaffold.

Physicochemical characterization of the biocomposite scaffolds
The surface morphologies of 3D CORAGRAF with and without PLGA MS were studied under
a scanning electron microscope (SEM; Model JEOL JSM-6360, Japan), and the elemental
composition of the scaffolds was semi-quantitatively investigated using SEM-energy
dispersive X-ray spectroscopy (SEM-EDX) (INCA Energy 200, Oxford Inst). To determine
the average size of the fabricated MS, the samples were run through Malvern Mastersizer 2000
particle size analyzer (Malvern Instruments Ltd., England). Furthermore, microtomography
(micro-CT) system (Scanco Medical XtremeCT HRpQCT) was used to quantify the 3D
microstructural properties of the scaffolds, and the Brunauer–Emmett–Teller (BET-AutosorbiQ2) specific surface area of the biocomposites was measured from the nitrogen adsorption–
desorption isotherms. To identify the functional groups of the scaffolds, Fourier-transform
infrared spectroscopy (FTIR; Bruker, tensor 27; Germany) analysis was performed in a
frequency range of 4000–400 cm−1. The X-ray diffraction (XRD) patterns of the composites
were obtained using PANanalytical Empyrean XRD (USA) with monochromatic CuKa
radiation (λ = 1.54056 A), operated at 45 kV, 40 mA, step size of 0.026°, and a scanning rate
of 0.1 s−1 over a 2θ range from 20° to 80°. The glass transition temperature of the PLGA MS
was determined using differential scanning calorimeter (DSC, METTLER TOLEDO 820C-
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Error ±0.25−1°C) at a heating rate of 4°C/min. The weight loss and thermal stability of the
scaffolds were ascertained by thermogravimetric analysis (TGA, Mettler Toledo-SDTA851) at
a heating rate of 5○C/min and temperature of 30°C–800○C.

Cell morphology
After incubation for a few days, the samples were removed from the culture plates, washed
thrice with PBS, and fixed with 3% glutaraldehyde in PBS for 24 h at 4°C. Subsequently, the
samples were thoroughly washed with PBS and sequentially dehydrated twice in 30%, 50%,
70%, 80%, 90%, 95%, and 100% ethanol for 15 min each. The fixed samples were freezedried, sputter-coated with gold, and examined under SEM.

Isolation of MSC
Human bone marrow aspiration from the femoral medullary canal was performed
concomitantly during knee arthroplasty at the University Malaya Medical Center (UMMC),
Malaysia, with the patient under general anesthesia. The procedure was performed under
aseptic conditions by an experienced surgeon. Prior to knee arthroplasty, informed written
consent was obtained from each bone marrow donor. During knee arthroplasty, approximately
2 ml of bone marrow sample were aspirated from the patient’s femoral medullary canal using
a needle and syringe, transferred into a BD vacutainer, and transported to the cell culture lab.
The bone marrow samples were collected from the operating room only after completion of the
bone marrow aspiration procedure by the surgeon. The bone marrow collection procedure for
the present study was approved by the medical ethics committee (Approval ID No.
MECID.NO: 201412-859, UMMC). The cell isolation procedure was performed in accordance
with the approved guidelines of UMMC.
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Subsequently human bone marrow stromal cells were harvested and cultured as
previously described.35

Cell seeding and culture
The MSC suspension at a density of 3.0 × 104 cells/mL was seeded onto the PLGA MS
incorporated CORAGRAF. Subsequently, the MSC-seeded scaffolds were left for 28 days in
DMEM to induce osteogenic differentiation, and the medium was changed every 4 days.

In vitro release of PDGF-BB
In a 6-well plate, 10 µg of the dispersed PLGA MS were incubated in 1 ml of DMEM, and the
medium was collected at certain time points. The procedure was simultaneously repeated with
PLGA MS embedded onto the CORAGRAF. The media collected were assessed using the
PDGF-BB ELISA kit (eBioscience, USA) according to manufacturer’s instructions.

Confocal microscopy
Confocal microscopy was performed to determine the cell density on the surface of the
scaffolds and infiltration of the cells into the pores of the scaffolds. The MSC-seeded scaffolds
were stained with Hoechst 33342 cell-permanent nuclear stain (Life Technologies, Invitrogen,
USA). The molecular probes got bound to the A-T regions of the DNA and emitted a blue
fluorescence at 460 nm. The morphology and distribution of the MS in the scaffold were
examined using SEM and laser scanning confocal microscopy (Leica TCS-SP5 II; Leica
Microsystem, Mannheim, Germany). The scaffolds with human bone marrow stromal stem
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cells were stained according to the manufacturer’s protocol and analyzed using confocal
microscopy (Leica TCS-SP5 II; Leica Microsystem, Mannheim, Germany).

Alamar Blue assay
The nontoxic Alamar Blue assay (Invitrogen) was performed to measure the cell proliferation
in PLGA MS loaded CORAGRAF on days 0, 3, and 7 post-seeding. In a 96-well plate, 1/10th
volume of the AlamarBlue® reagent was added to the cells in the culture medium (cell density
= 1.0 × 104 cells/mL), and the mixture was incubated in 5% CO2 at 37C for 4 h. Subsequently,
a 100-µl aliquot was placed in a microtiter plate reader (Biotek, Epoch USA) and the
absorbance measurements were determined at 570 and 600 nm.

Osteocalcin ELISA
Osteocalcin activity on the scaffolds was determined on days 0, 3, and 7 using the osteocalcin
ELISA assay kit (eBioscience). First, the cell culture sample was incubated at room
temperature (18 to 25°C) for 2 h, and then, following a few wash procedures according to the
manufacturer’s protocol, 100μl substrate solution was added and incubated for 10 minutes.
Subsequently, the absorbance measurements were determined at 450 nm using a
spectrophotometer (Biotek, Epoch USA).

Alizarin red staining
Alizarin red staining was performed to identify the calcium deposits on the scaffolds. A total
of 500 µl of Alizarin red were added to the cell culture plate and incubated for 20 min.
Subsequently, the plate was continuously washed with PBS to remove any additional stain.
The culture plate images were captured using (Nikon, Japan) T3 microscope.
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Gene expression
To examine the level of osteogenic differentiation, gene xpression was employed according to
a previously established method.36

Results
Morphological analysis of the scaffolds
SEM analysis was performed to assess the patterns of pore diameter and surface of the scaffolds
(Fig. 1a–c). While the pure CORAGRAF had a pore diameter of 107–315-µm, the pores of
PLGA MS loaded CORAGRAF were partially infiltrated with MS and a few pores remained
open. Analysis of the PLGA MS using Mastersizer (Fig. 1d) indicated that the average particle
size to volume % was around 137 µm. Furthermore, confocal images confirmed (Fig. 2a–c)
that the PDGF-BB-loaded PLGA MS infiltrated up to 599-µm thickness of the 3D scaffold
material. The PLGA MS loaded with FITC-BSA are shown in Fig. 2c. The 3D image obtained
by incorporating multiple series of images collected by confocal laser microscopy further aided
the investigation of PLGA infiltration.

Porosity analysis
The 3D CORAGRAF scaffolds with and without PLGA MS were subjected to micro-CT
examination (Fig. 3a, b). The total volume of the 3D CORAGRAF without PLGA MS was
432.81 mm3. The material volume of the CORAGRAF without PLGA MS was 169.22 mm3,
while that of the CORAGRAF with the PLGA MS was 288.58 mm3. The ratio of the total
volume and material volume for the CORAGRAF without and with PLGA MS was about 0.39
and 0.66, respectively. These results clearly indicated that almost 50% of the CORAGRAF was
infiltrated with PDGF-BB-loaded PLGA MS. The porosity of the CORAGRAF without the
PLGA MS was about 60%; however, after PLGA MS incorporation, the porosity decreased to
11

about 33%. Furthermore, micro-CT was also employed to measure the material surface area of
the CORAGRAF without and with MS, which was 2031.12 and 2199.01mm2, respectively.
Comparative BET analysis (Fig. 4a, b) of the scaffold materials revealed that both the
scaffolds possessed a typical type IV isotherm with a well-defined presence of mesopores.
However, the pore-size distribution calculated by Barret–Joyner–Halenda (BJH) method
revealed that the total pore volume of the mesopores was considerably lower in CORAGRAF
with PLGA MS, when compared with that in CORAGRAF without PLGA MS, which could
be owing to the high total volume of the macropores assigned to the PLGA MS. In addition,
CORAGRAF without PLGA MS showed a significantly higher specific surface area (32.67
m2/g) and specific pore volume (0.019 cm3/g), when compared with CORAGRAF with PLGA
MS (2.36 m2/g and 0.0063 cm3/g, respectively), which might be owing to the space occupied
by the PLGA MS.

Characterization of the scaffolds
FTIR spectroscopy was employed to study the functional groups of the scaffolds, and the
results are shown in Fig. 5a. Both the CORAGRAF scaffolds with and without PLGA MS
showed the characteristic peaks of carbonate, including the absorption bands of 706, 853, 1081,
and 1447 cm-1 corresponding to in-plane bending, out-of-plane bending, symmetric stretching,
and asymmetric stretching vibrations of the carbonate ions, respectively.37-40 However,
CORAGRAF with PLGA MS revealed four new absorption peaks (which were not observed
in CORAGRAF without PLGA MS) at 1176, 1265, 1753, and 2921 cm-1 corresponding to CO stretching, CH2 and CH3 asymmetric angular deformation, C=O stretching, and C-H
stretching vibrations, respectively,41-46 which proved the presence of PLGA in this
biocomposite.
The polymorphism of the scaffolds was examined by XRD, and the XRD patterns of
both the scaffolds are shown in Fig. 5b. The XRD spectra of the two scaffolds revealed sharp
12

peaks (indicated by * in Fig. 5b) corresponding to the crystalline planes of aragonite (JCPDS
card No. 41-1475). However, no peak of vaterite or calcite was noted, indicating that the
CORAGRAF was nearly pure aragonite.47 It should be noted that the encapsulated PLGA MS
did not show any peak in the XRD spectrum, suggesting that the addition of MS did not change
the CORAGRAF polymorphism and that the PLGA particles were amorphous in nature.48-49
Furthermore, to confirm the types of elements present in the CORAGRAF, EDS was employed,
and the results revealed the presence of moderate carbon levels and high carbon and calcium
levels (Fig. 5c). Moreover, the levels of these elements were not significantly altered after the
incorporation of PLGA MS.

DSC and TGA analyses
DSC and TGA analyses were conducted to further investigate the existence of PLGA MS in
the CORAGRAF, and the results are illustrated in Fig. 6a and 6b, respectively. While the DSC
thermogram of the CORAGRAF without PLGA MS did not show any peak in the designated
temperature range, that of the CORAGRAF with PLGA MS presented an endothermic peak at
51°C, corresponding to glass transition temperature (Tg) of PLGA.50 As indicated by the TGA
curve of pure CORAGRAF (Fig. 6b), the CaCO3 crystals revealed two main steps of weight
loss. The first step of weight loss was observed at around 300○C, exhibiting about 1% decrease
in weight, which can be attributed to evolution of CO2 from CaCO3.51 The second step of
weight loss was noted with a higher slope at 575°C–780°C, with a weight loss of about ~42%,
which indicated decomposition of CaCO3 to CaO.52-53 However, with the addition of PLGA
MS, the weight-loss pattern exhibited significant difference at 100°C–600°C, with a
considerably large amount (6%) of mass loss in CORAGRAF with PLGA MS, when compared
with that in pure CORAGRAF. In particular, the weight loss at 100°C–240°C can be attributed
to evaporation of the solvent, while that at 240°C–600°C can be related to decomposition of
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PLGA, with major decomposition corresponding to combustion of organic compound
occurring at 300°C (which overlapped with conversion of CaCO3 to CO2). Thus, it can be
concluded that the loading capacity of PLGA MS on the CORAGRAF was about 6%.

Cell viability and bone markers expression
Alamar Blue assay was performed to confirm cell viability throughout the experimental period
(Fig. 7b). The cell viability gradually increased, which was indicated by gradual dye reduction.
When compared with early time points (days 0 and 3), the latter time points presented
significant increase in cell viability (p <0.05). Moreover, confocal microscopy results
confirmed the DNA staining of the cells inside the coral graft (Fig. 7a).
As shown in Fig. 8a, considerably intense alizarin staining was evident in the bone
marrow stromal cell cultures treated with PLGA MS containing PDGF-BB, whereas no
positive staining was observed in the untreated cultures. Moreover, addition of PDGF-BB alone
to the cultures also showed positive alizarin staining, although the intensity of staining (red
dye) was less. These results suggested that the controlled release of PDGF-BB from the PLGA
MS incorporated onto the CORAGRAF scaffold may be beneficial for rapid cell expansion and
differentiation of stromal cells in 3D environment.
The controlled release of PDGF-BB was monitored using two different groups at
variable time points (Fig. 8b). Incubation of PLGA MS encapsulated with PDGF-BB in the
medium showed an initial burst and relatively high PDGF-BB release on days 0 and 3, and a
subsequent reduction in the release of the growth factor on day 7. In contrast, the PDGF-BBencapsulated PLGA MS incorporated onto the 3D CORAGRAF presented a relatively low
release of approximately 200 pg/ml PDGF-BB on days 0, 3, and 7, and the quantity was almost
the same at all the three time points. These results indicated that the release of PDGF-BB from
the PLGA MS incorporated 3D scaffold was well controlled. Furthermore, the cells treated
14

with PLGA MS containing PDGF-BB showed a twofold increase in the release of osteocalcin
on day 7 (Fig. 8c), when compared with that on day 0. In contrast, the cells treated with PDGFBB did not show any increase in osteocalcin release. Moreover, monitoring of the release of
osteocalcin from the PDGF-BB–PLGA MS–CORAGRAF scaffold at various time points
clearly indicated that the release of osteocalcin gradually increased, and was significant on day
21, when compared with that on earlier time points (Fig. 8d).
Subsequently, we examined the expression of an array of genes related to
osteogenesis, including Runx2, osteopontin (OPN) (Fig. 9a, b), collagen1, BMP2 (Fig. 10a,
b), bone gamma-carboxyglutamate (Gla) protein (BGALP), and osteonectin (ON) (Fig. 11a,
b) at different time points (days 0, 7, 14, and 21). On day 14, the expression of Runx2 and
OPN was significantly high, exhibiting approximately three- and twofold increase,
respectively, in the PDGF-BB-loaded PLGA MS–CORAGRAF scaffold, when compared
with that in the CORAGRAF scaffolds without PLGA MS and PDGF-BB. In addition, the
expressions of collagen1 and BMP2 were significantly increased (p < 0.05) in the PDGFBB-loaded PLGA MS–CORAGRAF scaffold, when compared with those in the
CORAGRAF scaffolds without PLGA MS and PDGF-BB; however, a decline in the
expressions of these genes was noted on day 21. Similarly, the levels of BGALP and ON
were also significantly higher (p<0.05) on day 14 in the PDGF-BB-loaded PLGA MS–
CORAGRAF scaffold, when compared with those in the CORAGRAF scaffolds without
PLGA MS and PDGF-BB.
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Discussion
The use of CORAGRAF in tissue engineering has gained potential interest owing to its
osteoconductive property and compatibility with the in vivo models.54 In the present study, to
improve its osteogenic differentiation property, we incorporated PLGA MS containing PDGFBB into the CORAGRAF scaffold for the controlled release of PDGF-BB. The SEM and
Mastersizer data indicated that the scaffold environment could support the growth and
differentiation of stromal cells. PLGA microspheres can be prepared using polymers of
different molecular weight that can influence the release profiles of target proteins. Herein, we
were capable of attaining the sustained release of PDGF-BB from PLGA50 microspheres
implanted in the scaffolds. Microsphere encapsulation of growth factors protects them from
degradation and deactivation when compared to direct supplementation of growth factors.
According to our in vitro bioactivity assay PDGF-BB has retained its bioactivity during loading
into PLGA microspheres. Loading of growth factors into the microspheres and subsequent
incorporation of such cargo into 3D scaffolds serves as a golden gate toward yielding a
controlled release profile for growth factors as well as sustaining their bioactivity for a longer
duration of time. Of note, the mechanism behind such findings is yet to be discovered. 55 In
clinical applications for the treatment of various bone ailments, the general biology of the bone
marrow stromal cells is the focus of interest.56 In the present study, although only a few pores
of the CORAGRAF were found to be infiltrated by PLGA MS, the CORAGRAF provided a
conducive environment for cell attachment on its surface. The cells attached onto the
CORAGRAF scaffold were randomly distributed within the pores and on the MS with an
average size of approximately 137 µm. Furthermore, the attached cells showed roughened
blebs and protrusions on the scaffold surface as well as a fibroblast-like appearance in some
regions. It has been previously reported that for achieving osteoblast-like behavior of the cells,
factors such as cell attachment efficiency and dissemination rely on the surface chemistry of
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the material,57 which was found to be positive in the present study. Furthermore, cell infiltration
into the PLGA MS incorporated CORAGRAF was random.
Previous studies have shown that coral is an excellent material for bone repair. Coral
grafting of osteochondral defects has been reported to produce new bone with characteristics
similar to those of normal subchondral bone in rabbits. Some pre-clinical reports and clinical
trials have confirmed that coral has good biocompatibility properties, and there have been no
reports on any rejection or collateral effects of coral. Moreover, it has been demonstrated that
coral can be used as an osteoconductor.58 However, some recent studies have proved that
stromal cell proliferation without growth factors in 3D scaffolds presents important limitations.
Consequently, many studies have used expensive commercial osteogenic media for cell
differentiation protocols.
In the present study, to achieve a cell confluence in a few days, similar to that obtained
in conventional culture plates, we employed the controlled growth factor release strategy for
releasing PDGF-BB from PLGA MS incorporated CORAGRAF scaffolds. PDGF-BB
stimulates the proliferation and recruitment of both periodontal ligament and bone cells in vitro.
Some in vivo studies have demonstrated that this growth factor enhances periodontal
regeneration in beagle dogs and non-human primates, heals bone defects in humans, and
enhances tissue regeneration, wound healing, and food ulcers.59 However, despite these
advantages, to maintain adequate therapeutic effect, PDGF-BB needs to be injected in high
dose or injected repeatedly.60 This is not practically applicable in most cases because of the
high costs and multiple administrations, which may necessitate additional surgical procedures
in vivo. Based on previous studies, we presumed that a slower release of PDGF-BB would keep
the growth factor intact and functionally active when released into the culture. In this regard,
we examined different strategies in vitro. It must be noted that alizarin staining of PDGF-BBencapsulated PLGA MS–CORAGRAF was too intense because of the presence of CaCO3 in
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CORAGRAF. Hence, the difference in staining between the 3D CORAGRAF with and without
PDGF-BB-encapsulated PLGA MS could not be assessed at the early stage of differentiation.
To the best of our knowledge, the present study is the first to report on rapid cell
expansion and osteogenic differentiation using CORAGRAF with PDGF-BB-encapsulated
PLGA MS. The morphological changes that occurred in the developed biocomposite provided
a suitable environment for the cells to get attached onto the surface. Although some decline in
the porosity was observed, these changes were inevitable owing to MS incorporation, which
favored greater surface area without affecting cell viability. Besides, scaffolds provide a
conducive environment for the growth of multipotent bone marrow derived stromal cells and
stimulate their osteoconductive and osteoinductive properties that contribute to bone repair.
Previous studies have shown that bone marrow stromal cells isolated from the marrow of mice,
rats, rabbits, dogs, and humans can be expanded in vitro. These cells can be differentiated into
osteoblast-like cells under certain conditions using commercial osteogenic media and multiple
growth factor supplements such as BMP.61
While PDGF-BB can induce proliferation of stromal cells and osteogenesis,62 there are
conflicting reports on the ability of PDGF-BB to inhibit osteogenic differentiation of osteoclast
cell lines in conventional culture flasks.63 It has been reported that markers of mature
osteoblasts such as alkaline phosphatase (ALP), osteocalcin, and type I collagen were inhibited
in the pre-osteocytic cell lines.64 However, some studies have demonstrated that PDGF-BB
does not alter the marker activity and mineralization in human stromal cells. It has been
indicated that imatinib-induced blockade of PDGFR-β produced opposing effects on the
differentiation of bone marrow stromal cells.65 Another study revealed that PDGF-BB with
peptides could improve the proliferation, differentiation, and early calcification of osteoblast
cells.66 Among the many major growth factors, PDGF-BB is the only growth factor currently
approved by the US-FDA for periodontal regeneration as a part of dental bone filling device.
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Furthermore, PDGF-BB has been incorporated into the MS in nanofibrous materials for
osteogenic response by slow delivery of the growth factor. Our previous studies have
demonstrated that some nanofibrous material and fucoidan-based scaffolds promoted
differentiation of bone marrow stromal cells with PDGF-BB supplementation.67-68 In the
present study, the release of the osteogenic differentiation marker, osteocalcin, confirmed that
the controlled release of PDGF-BB from the 3D scaffold is beneficial for osteogenic
differentiation. Despite the proven efficacy of PDGF-BB, its biomedical application is
complicated by its short biological half-life, systemic side effects, rapid clearance, and lack of
biomechanical property of the fibrous materials. Therefore, delivery systems that maximize the
therapeutic abilities of PDGF-BB are desirable, not only for enhancing bone formation, but
also for limiting undesirable biological reactions. In previous studies, to retain PDGF-BB at
the desired site for a prolonged time period, delivery via PLGA MS has been employed.36
Intramembranous ossification has been known as the usual mechanism deployed by the
biomaterials to induce bone formation; yet, endowing growth factors induces bone formation
via endochondral ossification. In spite of the fact that growth factors showed efficacy in
inducing osteogenesis, materials with osteoconductive traits are preferred for preclinical
studies. Nonetheless so far no studies have been devoted to comparing the performance of
biomimetic composites against growth factor supplementation in inducing osteogenesis. This
could be due to variety of the approaches employed for the purpose of fabricating a biomimetic
composite scaffold (either in nanoscale or microscale) and the choice of cell line, i.e. primary
or immortal cells. In fact some of the most crucial phenomenon involved in cell development
cascade such as ell contraction, ligation, and intracellular signaling are entitled to improvement
as a consequence of enhanced cell attachment. Overall, in comparison to two-dimensional
surface, 3D surface offers extra dimension which subsequently enhances the interactions
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between cell and the matrix as well as communications among cells, that were known vital to
the physiology of the cells.69
In the present study, the considerable increase (p < 0.05) in the expression of Runx2,
the central control gene within the osteoblast phenotype, on day 14 indicated the ability of the
developed scaffold system to support osteogenic differentiation. A previous work had
demonstrated that recombinant PDGF-BB can increase the activity of Runx2 as well as regulate
the downstream genes that maintain osteoblastic phenotype such as ALP. Moreover, while the
gene expression in human MSC seeded onto collagen nanofibers has been reported to mitigate
after passing of 3 weeks 70, in this study, the decline was yielded after day 14 in the developed
3D scaffold. These findings showed the short window between start and ending of the
differentiation phenomenon of human MSC grown on CORAGRAF with PDGF-BBencapsulated PLGA MS. Collagen is among crucial proteins expressed all through bone
differentiation. Herein, collagen gene expression was apparent in the early time point,
underscoring the primary cellular response to osteoinductive factors. Furthermore, in
accordance with previous reports, collagen was considerably expressed after day 7, and was
extracellularly produced leading to formation of an well integrated matrix within the scaffold
structure. This is a crucial step due to imperative role of collagen in stimulates pre-osteoblast
cell surface integrin that leads to activation of other core binding factors, which is known as an
essential part of osteogenesis.70 The expression of OPN (as a function of time) during the
differentiation phase (in presence or absent of extracellular molecules) followed the same
pattern as ON expression. Previous reports have demonstrated that the level of OPN is high
during the differentiation period.71 In addition, a previous study revealed that the OPN
expression escalated at the inauguration of osteodifferentiation and subsequently reduced
during 21 days of differentiation. In the same manner, another study reported a decline in OPN
expression in human MSC after 1 week of differentiation.
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The increase in BMP2 noted on day 14 in the present study primarily showed that the
developed scaffold could initiate particular differentiation of stem cells or progenitors to form
osteoblast-like cells. PDGF-BB-induced nodule formation was increased in the presence of
BMP2, indicating the strong probability of signaling between PDGF-BB and BMP2 pathways.
Moreover, PDGF-BB requires the presence of BMPs for the induction of bone formation,
suggesting that BMP signaling could be involved in PDGF-BB-based stem cell gene therapy.
In addition, this may also explain the ability of PDGF-BB to enhance bone formation in bone
but not in other tissues. It has been reported that the increased expression of some osteogenic
markers such as OPN and osteocalcin (BGALP) (p<0.05) indicates early osteogenic
differentiation phase was perfectly funded by 3D environment.72-73 Osteocalcin is
predominantly expressed by the osteoblastic phenotype, and is a reliable marker in osteogenic
differentiation and subsequent mineralization.74 In connection with the BGALP quantification
data, the post-proliferative osteoblast maker, osteocalcin, was also used in the present study to
assess the differentiation of human MSC on CORAGRAF with PDGF-BB-encapsulated PLGA
MS. The osteocalcin gene expression was observed at an early time point, which could be a
consequence of the partial differentiation of human MSC on the scaffold. This finding was
corresponding to the alizarin red staining results, which revealed that the staining was
inhomogeneous throughout the sample.
In conclusion, the developed PDGF-BB-encapsulated PLGA MS–CORAGRAF
scaffold system was capable of releasing PDGF-BB in a controlled manner for a prolonged
duration with significant reduction in burst effect. The stromal cell attachment, viability,
release of osteogenic differentiation markers such as osteocalcin, and upregulation of
osteogenic gene expression were considerably positive. The findings of this study could aid in
the development of a strategy to construct a powerful delivery vehicle to overcome a welldescribed challenge in tissue engineering.
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Figure legends

Figure 1a, b and c. Scanning electron microscopy of CORAGRAF (1a), The PLGA
microsphere encapsulated into the CORAGRAF (1b), CORAGRAF with PLGA microsphere
with human bone marrow stromal cells (1c). All the samples were fixed with 3%
glutaraldehyde in PBS for 24 h at 4 °C and processed. Figure 1d Mastersizer of PLGA
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microsphere using Malvern Mastersizer 2000 particle size analyzer showing the average
particle size of 137 µm.
Figure 2a-c. Infiltration of PLGA microsphere in CORAGRAF culture system using the
confocal microscopy. Green color indicates regions stained with FITC in the range of
approximately 599 µm of 3D CORAGRAF.
Figure 3 a & b Micro-ct analysis of CORAGRAF and CORAGRAF-PLGA loaded scaffold. A
Micro-CT system (Scanco medical XtremeCT HR pQCT) was used to quantify the 3D
microstructural properties
Figure 4 a & b BET of CORAGRAF (a) and PLGA microsphere encapsulated into
CORAGRAF (b). The Brunauer–Emmett–Teller (BET-Autosorb-iQ2) specific surface area of
the biocomposites was measured from the nitrogen adsorption–desorption isotherms. Inset is
the corresponding BJH pore size distribution.
Figure 5a-c. Fourier transmission infrared (FTIR) of biocomposites (a), XRD patterns of
scaffolds (b) and Energy Dispersive Spectroscopy of CORAGRAF and CORAGRAF PLGA
microsphere (c).
Figure 6a-b. DSC and TGA assay along with in-vitro degradation result of bio-scaffold. DSC
analysis was performed to confirm the state of PLGA microspheres in CORAGRAF (a), TGA
analysis was performed to confirm the existence of PLGA microspheres in CORAGRAF and
measure their corresponding weight ratio (b), Degradation of CORAGRAF-PLGA composite
scaffolds upon immersion in PBS for 10 days duration.
Figure 7a &b. Viability of the cells in the CORAGRAF- PLGA microsphere culture system.
Post-seeded cells on day 7 were fixed and viewed under the confocal microscope after staining
the scaffold with Hoechst 33342 cell-permanent nuclear stain. Blue dots indicate the DNAstained live cells (a), Viability of cell in CORAGRAF-PLGA microsphere loaded bone marrow
stromal cells at variable time points. *P <0.05 indicates the levels of significance (b).
Figure 8a Alizarin staining of the control cells and cells treated with the PDGF-BB released
from the microsphere and direct PDGF-BB treatment. 8b Release of the PDGF-BB from the
microsphere incubated in the media and CORAGRAF–microsphere culture system incubated
in the media. Figure 8c Release of the osteogenic marker osteocalcin at variable time points.
Figure 8d Release of osteocalcin in CORAGRAF-PLGA at variable time points. *P<0.05
indicates the level of significance of marker release.

Figure 9a, b. Quantitative expression of Runx2, osteopontin (OPN) in CORAGRAF,
CORAGRAF + PPDGF-BB and CORAGRAF+PLGA+PDGF-BB scaffolds during cell
differentiation. The total RNA was extracted from hMSCs cultured on the substrates (n = 6) at
day 0, 7, 14 and 21 using the RNeasy Mini Kit (Qiagen, Chatsworth, CA, USA). Following the
cDNA synthesis and qPCR, the relative gene expression was normalized to the GAPDH and
baseline expression. The data were represented as the means ± Standard deviation (SD). The
statistical significant was set at level P < 0.05, * Represents the comparison between
CORAGRAF, CORAGRAF + PPDGF-BB and CORAGRAF+PLGA+PDGF-BB
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Figure 10a, b. Quantitative expression of collagen 1 (Col1) and Bone morphogenic protein
(BMP2) in CORAGRAF, CORAGRAF + PPDGF-BB and CORAGRAF+PLGA+PDGF-BB
scaffolds during cell differentiation. The total RNA was extracted from hMSCs cultured on the
substrates (n = 6) at day 0, 7, 14 and 21 using the RNeasy Mini Kit (Qiagen, Chatsworth, CA,
USA). Following the cDNA synthesis and qPCR, the relative gene expression was normalized
to the GAPDH and baseline expression. The data were represented as the means ± Standard
deviation (SD). The statistical significant was set at level P < 0.05, * Represents the comparison
between CORAGRAF, CORAGRAF + PPDGF-BB and CORAGRAF+PLGA+PDGF-BB
Figure 11a, b. Quantitative expression of BGALP and osteonectin (ON )in CORAGRAF,
CORAGRAF + PPDGF-BB and CORAGRAF+PLGA+PDGF-BB scaffolds during cell
differentiation. The total RNA was extracted from hMSCs cultured on the substrates (n = 6) at
day 0, 7, 14 and 21 using the RNeasy Mini Kit (Qiagen, Chatsworth, CA, USA). Following the
cDNA synthesis and qPCR, the relative gene expression was normalized to the GAPDH and
baseline expression. The data were represented as the means ± Standard deviation (SD). The
statistical significant was set at level P < 0.05, * Represents the comparison between
CORAGRAF, CORAGRAF + PPDGF-BB and CORAGRAF+PLGA+PDGF-BB
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